Who Should NOT Take Super Tadarise 20 mg? (Business Opportunities - Advertising Service)

USNetAds > Business Opportunities > Advertising Service

Item ID 133549468 in Category: Business Opportunities - Advertising Service

Who Should NOT Take Super Tadarise 20 mg?


Free Online Advertising
Free Internet Web Site Advertising.


UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.


Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.

Super Tadarise 20 mg is a combination medication that integrates Tadalafil and Dapoxetine to effectively address both Erectile Dysfunction (ED) and Premature Ejaculation. Tadalafil, a PDE5 Inhibitor, enhances blood flow to the penis during sexual stimulation, while Dapoxetine, a Selective Serotonin Reuptake Inhibitor (SSRI), elevates serotonin levels in nerves, improving control over ejaculation.

Usage of Super Tadarise 20 mg:
Super Tadarise 20 mg is designed to treat male sexual issues such as Erectile Dysfunction and Premature Ejaculation. ED, characterized by the inability to achieve or maintain an erection during sexual intercourse, requires attention. Premature Ejaculation occurs when ejaculation happens sooner than expected, often preceding or shortly after penetration.

Mechanism of Action:
Tadalafil inhibits Phosphodiesterase type 5, preventing the degradation of cGMP (Cyclic Guanosine Monophosphate). This promotes relaxation of penile veins, facilitating an erection during sexual activity. Dapoxetine, a selective serotonin reuptake inhibitor, delays the ejaculation reflex, extending the Intra-Vaginal Ejaculatory Latency time (IELT) and preventing Premature Ejaculation.

Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : All Cities
Last Update : May 28, 2025 6:39 AM
Number of Views: 30
Item  Owner  : julia
Contact Email: (None)
Contact Phone: (None)

Friendly reminder: Click here to read some tips.
USNetAds > Business Opportunities > Advertising Service
 © 2025 USNetAds.com
2025-08-01 (0.468 sec)